Time-to-next-treatment and Time-to-next-systemic Treatment in Patients Included in the PROCLIPI Registry

Time to next treatment (TTNT), a recently established endpoint in clinical trials for primary cutaneous T-cell lymphomas (CTCL), represents a useful indication as a surrogate marker for the durtion of clinical benefit. It is a unique parameter which allows to take into consideration not only the duration of clinical activity of a specific drug regimen but also the patient compliance and tolerability of the treatment schedule. A series of data clearly support the short duration of TTNT in patients with CTCL. The present paper analyses TTNT and time to next systemic treatment (TTNsT) in the PROCLIPI cohort of patients. PROCLIPI registry was established since 2,015 and includes all the new diagnoses of mycosis fungoides/Sézary syndrome (MF/SS) patients in CTCL referral centers worldwide. Untill now, a total of 4,756 treatments were registered among which 2,647 at visit 1. According to the treatment category, 2,364 skin-directed therapies (SDT) were registered (49.7%) and 1,810 systemic (38%), while 482 patients were managed through an expectant policy. TTNT analysis was performed in 2,969 cases who received a further treatment. Median TTNT was 136 days corresponding to 4.5 months for the entire cohort (range from 1 month to 5.7 years. As to TTNsT among 1,743 cases, median values were 169 days (corresponding to 5.6 months (up to 4.3 years). This preliminary analysis confirms the short duration of TTNT and TTNsT in MF/SS patients diagnosed in treated in real life, supporting the importance of identifying clinical and biological markers with predictive value on treatment benefit as well as new treatment approaches aimed to improve disease outcome. on behalf the CLIC Alliance, CLIC Treatment Working Group, EORTC and ISCL collaborative study groups and all the PROCLIPI centers. Time to next treatment (TTNT), a recently established endpoint in clinical trials for primary cutaneous T-cell lymphomas (CTCL), represents a useful indication as a surrogate marker for the durtion of clinical benefit. It is a unique parameter which allows to take into consideration not only the duration of clinical activity of a specific drug regimen but also the patient compliance and tolerability of the treatment schedule. A series of data clearly support the short duration of TTNT in patients with CTCL. The present paper analyses TTNT and time to next systemic treatment (TTNsT) in the PROCLIPI cohort of patients. PROCLIPI registry was established since 2,015 and includes all the new diagnoses of mycosis fungoides/Sézary syndrome (MF/SS) patients in CTCL referral centers worldwide. Untill now, a total of 4,756 treatments were registered among which 2,647 at visit 1. According to the treatment category, 2,364 skin-directed therapies (SDT) were registered (49.7%) and 1,810 systemic (38%), while 482 patients were managed through an expectant policy. TTNT analysis was performed in 2,969 cases who received a further treatment. Median TTNT was 136 days corresponding to 4.5 months for the entire cohort (range from 1 month to 5.7 years. As to TTNsT among 1,743 cases, median values were 169 days (corresponding to 5.6 months (up to 4.3 years). This preliminary analysis confirms the short duration of TTNT and TTNsT in MF/SS patients diagnosed in treated in real life, supporting the importance of identifying clinical and biological markers with predictive value on treatment benefit as well as new treatment approaches aimed to improve disease outcome. on behalf the CLIC Alliance, CLIC Treatment Working Group, EORTC and ISCL collaborative study groups and all the PROCLIPI centers.